{"name":"Jagannath, Sundar, M.D.","slug":"jagannath-sundar-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBXeFQ0cWJxazZaS1oxdmpId08wNjNSTHJ6UTNiZTBoanR3NVJLR0xaUl9MSUJLZkdOR2Jva3ZheVQ5R1ppeG1lN1VwSTk4SnF5TThjbXIwVGR1bVg5bXBuTDBsVVJITWZ6SndBRXhOWQ?oc=5","date":"2025-11-05","type":"pipeline","source":"MedPage Today","summary":"Achieving Cure in Multiple Myeloma - MedPage Today","headline":"Achieving Cure in Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPUE1KRmthTmhUeTNJQVo1ai10VGY5ZmExZFFVeWVhbXFCUXFvd2k0bkNTYUVSbnFqMnZvWHJFZ2V6V002SHJfem4ya01DWS1KN21DYXNMalY3MFdsWDlJVG9PNFBTOU9HbFdSR2Q1cjRuYVpaTzF1NWk3bU12bmZoajVyaF94LW9RcENXVUlrcVNlYk9HUFM3bXNKU0F6dU1qX1E?oc=5","date":"2025-09-10","type":"pipeline","source":"CancerNetwork","summary":"Evaluating the Proximity and Impact of a Cure in Multiple Myeloma - CancerNetwork","headline":"Evaluating the Proximity and Impact of a Cure in Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE5wTWI5LUJjb3VDOG1pWElDdGF5UDhhV2ZRQXFzUmg3Q25saTYyZW52Ti1wcGRfMzl5QlJlanVkRFdJbjF4OUJ5VW15d1Y4eTlGcDFGZmxZcnAzQQ?oc=5","date":"2025-09-07","type":"pipeline","source":"Oncodaily","summary":"Highlights from SOHO 2025 Annual Meeting - Oncodaily","headline":"Highlights from SOHO 2025 Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOTBHT1FhZjVsUmJyekg1TGZ4VkZuS0VKdWtjSTNWUHlTRjdXTnBvY2o5aXRxcmo1aUZCTS0zMnZQQTFQTTJRT3IxcF92ZUt3Unp6anNlUzYtYWdKNUIwZlNLdXBYcUxaYW96dncwWnBza0xiQmdRZU5JeU03M1NMVllYa1I2WTloS0xYenpnMHctc0lKS2pKZi1uSThzVTNyZUVUQmpERDkyVTBkQTA0NnJPczVjNlJJRHA0?oc=5","date":"2025-07-07","type":"regulatory","source":"Pharmaceutical Executive","summary":"FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Relapsed or Refractory Multiple Myeloma - Pharmaceutical Executive","headline":"FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Relapsed or Refractory Multiple Myeloma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxONUNRMlFObkNtaHYwVG1YT0RocUkzbzJ2a2hKVF9lM2JFbFpvcGx4V3FXRVRoYTNrVjFyXzZIRTJRMF85akFDQXZEeDdxSWhiNm9sWUtUN1ZFUXN4em91MkVDakpON1ZlbnpFR2huYmJTQzZWZFlDd0tpTUpkeG1nQ01BZ1BiTHlpdzRYd2pxUDJEVy1nR2ZpZURlMWlwV0ZHMWVkOE9kTTExLWFJQ2N2bUZmZDFHN1BVa1RGSQ?oc=5","date":"2025-07-02","type":"regulatory","source":"Healio","summary":"FDA approves Lynozyfic for relapsed, refractory multiple myeloma - Healio","headline":"FDA approves Lynozyfic for relapsed, refractory multiple myeloma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOZHNSTGQxTmdPbGthTlFIbWJFa01jRVlmRzJMZ09rQW5velJSb3NGRW1zODVCOGhpc1VVUmxjT2ZDa085LWotOFlvLWpaUG5GNzFkRlRUM3ZyRGNMemx3TnFSU2kxNDNzVy1EX3kzd0NiM3A3UU5nZ1hicmYwQ0prR1dSNDJuN2F0OFhIaTh5aks3cDZkai0wU09RelJMUi14Q3RqWldSeUFtWnROOEVYMHp0bW9abVhyMGpKdXRPcw?oc=5","date":"2024-04-09","type":"trial","source":"Oncology News Central","summary":"Bispecific Linvoseltamab Yielded Deep, Durable Responses in RRMM in Early Trial - Oncology News Central","headline":"Bispecific Linvoseltamab Yielded Deep, Durable Responses in RRMM in Early Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNMS0wNUxKdFZNeGctMzJSVWhkRTNhVnpCN1JuWXJNUGZwUTRIUThHalQ1Y2l3bXRhUHYyd1BDbTBVWWI0T01haUZqNU1Wa1dCOXpSanRnSTVwM254Ukl6b0x0OEZfOUJaSmZqNEY4NFBKRms0RDFtanlaWk5KS3FGNTZXOHhIZFUwYW5NZGV3aDd1cktNenlTVVZEbHFheVZGM2N0UHFycDFyN3ZpSnU1cUpMbG8xNzJhS2VRMWlZTkRrYVE3RXhXUTREMUZwQmpmUUxwUW1qU0JVUmpidWFJZ3hOWmJwby1IYWZLSGY1WQ?oc=5","date":"2024-03-18","type":"regulatory","source":"Pharmaceutical Executive","summary":"FDA’s Oncologic Drugs Advisory Committee Recommends Earlier Treatment with Carvykti for Relapsed or Refractory Multiple Myeloma - Pharmaceutical Executive","headline":"FDA’s Oncologic Drugs Advisory Committee Recommends Earlier Treatment with Carvykti for Relapsed or Refractory Multiple ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOSXZiYXJOSnVMT3NtcW1JWkNOOUhFV0tUUnRVSkdYcnBxZVREN1pncnZUMy1tWVVHaUZ6MmFYUEN4eHNIVkVBWkxLYm1SMUU0Q3lrX3c0V3Q1UDlvVnYyaW9URGtRWGZZMkJYVkdoY09QeWE1V090eGdtT1NWWWJjR1RzLVhoLW5NMHdmaE1KVWJQWjdh?oc=5","date":"2022-03-01","type":"regulatory","source":"Medical Professionals Reference","summary":"Carvykti Approved for Relapsed/Refractory Multiple Myeloma - Medical Professionals Reference","headline":"Carvykti Approved for Relapsed/Refractory Multiple Myeloma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNeXh5V2RVNXJlM00yNFdIaWRjdUdjQUZKejVPRmRlYWdvOUhvRVdwajlrSWc1elc3NHltbVhFYkZXMEx2c1VwV0xrQXJPUWlOeE5vQzlSTHpuYnJiQ21NNmpLbFU3X01yNTYtMEtXMlFoZ0NnUG9JWHRkODJrWGRuT1o2dW9sdVNWbXhPWFNBc2NROGw3eUJOZFdJUmFBODB5MUp2aVdmNHZZNW01LUw0RFVlOGt6QzJHdUZlN0xWY1BUVFNTa2liZGhGSUxqUzkteFJGamJiYjJSV0hIcG5yekFoUllpbWs4QnFkWkNYMkI4bUtndWJ4b29Vdw?oc=5","date":"2020-08-30","type":"trial","source":"Karyopharm","summary":"Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine - Karyopharm","headline":"Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9kZlcyWnFLM0NuRDUzbmxIbk1wQXZZQzlIVE15WWUxUGNJUnduM3VLN1pWdTBYSmR0QUQzdTRBTGE1Z1ZuYlFZcVZ2YUttTXVaa25KTnBRM01iV19JQkc4MA?oc=5","date":"2019-05-02","type":"pipeline","source":"NEJM","summary":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma - NEJM","headline":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE10aGVoZURSM1JyajY5dFZiOG5uSUx1MmFtOW5hOF9tbUh5bnd5Q01rVk5qM0JONnZzZUtJT2JFcUFGaWkzVXFuV2thUEVMRzhPV0twYlRqSVg1NVY1QTVfQnJka2pMYjVLQzE2b2hSbXVvdElpaVA2cm56OA?oc=5","date":"2006-02-08","type":"trial","source":"acsjournals.onlinelibrary.wiley.com","summary":"Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma: - acsjournals.onlinelibrary.wiley.com","headline":"Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}